PMID- 11230617
OWN - NLM
STAT- MEDLINE
DCOM- 20010524
LR  - 20190605
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 107
IP  - 3
DP  - 2001 Mar
TI  - Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific 
      sensitization, and atopic manifestation in longitudinally followed early Bacille 
      Calmette-Guerin-vaccinated and nonvaccinated children.
PG  - E36
AB  - BACKGROUND: Bacille Calmette-Guerin (BCG) is a strong T helper 1 incentive and, 
      thus, may contribute to a decreased risk of T helper 2-dependent atopic disease. 
      OBJECTIVE: To investigate the natural course of specific immunoglobulin E (IgE) 
      responses and atopic disease in BCG-vaccinated and nonvaccinated children. 
      PARTICIPANTS: Seven hundred seventy-four children from a prospectively followed 
      birth cohort. OUTCOME MEASURES: Physical examination and case history were 
      performed at 3, 6, 12, 18, 24, 36, 48, 60, 72, and 84 months of age. Total and 
      specific serum IgE levels to 9 common inhalant and food allergens were determined 
      (CAP; Pharmacia, Freiburg, Germany) at 12, 24, 36, 60, 72, and 84 months of age. 
      Purified protein derivative (PPD) skin testing was performed at 84 months. 
      RESULTS: Period and lifetime prevalences of atopic dermatitis and recurrent 
      wheezing tended to be lower in the BCG-vaccinated group early in life, whereas no 
      such trend was found after the second birthday or for allergic rhinitis. The 
      proportion of children remaining free of clinical manifestations tended to be 
      higher in the BCG-vaccinated group but differences decreased over time. No 
      statistically significant differences were found for total IgE levels (median). 
      Atopic sensitization tended to be lower among BCG-vaccinated children during the 
      first 2 years of life. The diameter of the skin reaction to PPD did not correlate 
      with total serum IgE. Clinical and serologic correlates of atopy were not 
      significantly different between children with a skin test diameter of >/=5 mm and 
      those with a smaller diameter. CONCLUSION: These results do not support the 
      hypothesis that BCG vaccination in early infancy is associated with a 
      subsequently markedly decreased risk of atopic sensitization or allergy. In 
      addition, PPD skin test reactivity was not impaired in atopic individuals.
FAU - Gruber, C
AU  - Gruber C
AD  - Children's Hospital, Charite Campus Virchow, Medical Faculty of Humboldt 
      Universitat, Berlin, Germany. christoph.grueber@charite.de
FAU - Kulig, M
AU  - Kulig M
FAU - Bergmann, R
AU  - Bergmann R
FAU - Guggenmoos-Holzmann, I
AU  - Guggenmoos-Holzmann I
FAU - Wahn, U
AU  - Wahn U
CN  - MAS-90 Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (BCG Vaccine)
RN  - 0 (Tuberculin)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
CIN - Pediatrics. 2002 Feb;109(2):346-7. PMID: 11826222
MH  - BCG Vaccine/*immunology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Hypersensitivity/epidemiology
MH  - *Hypersensitivity, Delayed/epidemiology
MH  - Immunoglobulin E/*immunology
MH  - Infant
MH  - Infant, Newborn
MH  - Longitudinal Studies
MH  - Male
MH  - Risk
MH  - Skin Tests
MH  - Tuberculin/*immunology
MH  - Tuberculin Test
EDAT- 2001/03/07 10:00
MHDA- 2001/05/26 10:01
CRDT- 2001/03/07 10:00
PHST- 2001/03/07 10:00 [pubmed]
PHST- 2001/05/26 10:01 [medline]
PHST- 2001/03/07 10:00 [entrez]
AID - 10.1542/peds.107.3.e36 [doi]
PST - ppublish
SO  - Pediatrics. 2001 Mar;107(3):E36. doi: 10.1542/peds.107.3.e36.